Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics

9 May 2007

Abstract excerpt

Prognostic models for multiple myeloma have been fraught with tremendous heterogeneity in outcome among subgroups. In the context of Total Therapy 2, a tandem transplant trial for newly diagnosed myeloma, comprehensive information was available in 220 patients on standard prognostic factors (SPF), magnetic resonance imaging (MRI)-defined focal lesions, cytogenetic abnormalities (CA),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lymphoma Diagnosis and Treatment
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17489983
DOI: 10.1111/j.1365-2141.2007.06586.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular geneticsPMID 17489983Read ↗

Prognostic significance of copy-number alterations in multiple myeloma.Semantic proximity Read ↗

Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical useSemantic proximity Read ↗

Gene Expression Profiling in Multiple Myeloma—Reporting of Entities, Risk, and Targets in Clinical RoutineSemantic proximity Read ↗

Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cellsSemantic proximity Read ↗

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).Semantic proximity Read ↗

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1Semantic proximity Read ↗

The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic eventSemantic proximity Read ↗

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 studySemantic proximity Read ↗

Clinical applicability and prognostic significance of molecular response assessed by fluorescent‐<scp>PCR</scp>of immunoglobulin genes in multiple myeloma. Results from a<scp>GEM</scp>/<scp>PETHEMA</scp>studySemantic proximity Read ↗

Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implicationsSemantic proximity Read ↗

Transcriptional features of multiple myeloma patients with chromosome 1q gainSemantic proximity Read ↗

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.